• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利伐沙班致自发性血胸:一例罕见病例报告及文献综述

Rivaroxaban-induced spontaneous hemothorax: a rare case report and literature review.

作者信息

Li Xiaolong, Xu Shuhao, Zeng Chunfang, Han Ding, Wang Xin

机构信息

Pulmonary and Critical Care Medicine, Deyang People's Hospital, Deyang, China.

Department of Stomatology, Deyang People's Hospital, Deyang, China.

出版信息

Front Med (Lausanne). 2025 Jul 29;12:1641092. doi: 10.3389/fmed.2025.1641092. eCollection 2025.

DOI:10.3389/fmed.2025.1641092
PMID:40800137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12339356/
Abstract

INTRODUCTION

Rivaroxaban, a novel oral anticoagulant, is widely used in patients with non-valvular atrial fibrillation. Bleeding events during rivaroxaban therapy most commonly include gastrointestinal bleeding and intracranial hemorrhage, while spontaneous hemothorax is exceedingly rare. We report a case of spontaneous hemothorax occurring during rivaroxaban administration.

METHODS

We report the case of a patient presenting primarily with dyspnea. The patient had been on long-term oral rivaroxaban for atrial fibrillation. Physical examination upon admission revealed diminished breath sounds in the left lung. Computed tomography imaging demonstrated a large left-sided pleural effusion with adjacent pulmonary atelectasis. Laboratory tests indicated significant coagulation abnormalities. After admission, the patient underwent therapeutic thoracentesis and chest tube placement, with bloody pleural fluid observed in the drainage. Due to the marked coagulation abnormalities on admission, the patient received fresh frozen plasma transfusion. Further history-taking revealed recent use of oral fluconazole. A review of the literature suggested that the spontaneous hemothorax might be associated with the concurrent use of rivaroxaban and fluconazole.

RESULTS

Following treatment, a follow-up computed tomography scan 3 months later showed no evidence of recurrent hemothorax.

DISCUSSION

Concomitant administration of rivaroxaban and fluconazole significantly increases the risk of bleeding events, necessitating clinician vigilance regarding potential drug-drug interactions when formulating therapeutic regimens.

摘要

引言

利伐沙班是一种新型口服抗凝剂,广泛应用于非瓣膜性心房颤动患者。利伐沙班治疗期间的出血事件最常见的包括胃肠道出血和颅内出血,而自发性血胸极为罕见。我们报告一例在服用利伐沙班期间发生自发性血胸的病例。

方法

我们报告一例主要表现为呼吸困难的患者。该患者长期口服利伐沙班治疗心房颤动。入院时体格检查发现左肺呼吸音减弱。计算机断层扫描成像显示左侧大量胸腔积液伴相邻肺不张。实验室检查表明存在明显的凝血异常。入院后,患者接受了治疗性胸腔穿刺和胸腔闭式引流管置入,引流液中观察到血性胸腔积液。由于入院时存在明显的凝血异常,患者接受了新鲜冰冻血浆输注。进一步询问病史发现患者近期使用过口服氟康唑。文献回顾提示自发性血胸可能与利伐沙班和氟康唑的同时使用有关。

结果

治疗后,3个月后的随访计算机断层扫描显示无复发性血胸迹象。

讨论

利伐沙班和氟康唑同时使用显著增加出血事件风险,临床医生在制定治疗方案时必须警惕潜在的药物相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1815/12339356/e3f96ebeafc1/fmed-12-1641092-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1815/12339356/33ccbcdf4fbb/fmed-12-1641092-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1815/12339356/4c2a45bf9be2/fmed-12-1641092-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1815/12339356/4e37c696de0f/fmed-12-1641092-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1815/12339356/e3f96ebeafc1/fmed-12-1641092-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1815/12339356/33ccbcdf4fbb/fmed-12-1641092-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1815/12339356/4c2a45bf9be2/fmed-12-1641092-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1815/12339356/4e37c696de0f/fmed-12-1641092-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1815/12339356/e3f96ebeafc1/fmed-12-1641092-g004.jpg

相似文献

1
Rivaroxaban-induced spontaneous hemothorax: a rare case report and literature review.利伐沙班致自发性血胸:一例罕见病例报告及文献综述
Front Med (Lausanne). 2025 Jul 29;12:1641092. doi: 10.3389/fmed.2025.1641092. eCollection 2025.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.利伐沙班和达比加群在心房颤动治疗患者中的出血结局:一项系统评价和荟萃分析。
BMC Cardiovasc Disord. 2017 Jan 6;17(1):15. doi: 10.1186/s12872-016-0449-2.
4
Large extrapleural hematoma in a patient with Stanford type B acute aortic dissection: a case report.一名斯坦福B型急性主动脉夹层患者出现巨大胸膜外血肿:病例报告
J Med Case Rep. 2025 Jul 15;19(1):348. doi: 10.1186/s13256-025-05400-1.
5
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.在心房颤动患者中,Xa因子抑制剂与维生素K拮抗剂预防脑栓塞或全身性栓塞的比较
Cochrane Database Syst Rev. 2013 Aug 8(8):CD008980. doi: 10.1002/14651858.CD008980.pub2.
6
Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis.经导管主动脉瓣置换术(TAVR)后使用非维生素K拮抗剂口服抗凝药(NOACs):一项网状荟萃分析。
Cochrane Database Syst Rev. 2025 Feb 24;2(2):CD013745. doi: 10.1002/14651858.CD013745.pub2.
7
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair.在择期初次髋关节或膝关节置换术或髋部骨折修复中,直接凝血因子Xa抑制剂与低分子量肝素或维生素K拮抗剂用于预防静脉血栓栓塞的比较
Cochrane Database Syst Rev. 2025 Jan 27;1(1):CD011762. doi: 10.1002/14651858.CD011762.pub2.
8
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
9
Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee surgery: a systematic review and network meta-analysis.择期髋关节或膝关节手术患者预防出血的药物干预措施:系统评价和网络荟萃分析。
Cochrane Database Syst Rev. 2024 Jan 16;1(1):CD013295. doi: 10.1002/14651858.CD013295.pub2.
10
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.抗血小板和抗凝药物用于抗磷脂综合征患者中风和其他血栓栓塞事件的二级预防。
Cochrane Database Syst Rev. 2017 Oct 2;10(10):CD012169. doi: 10.1002/14651858.CD012169.pub2.

本文引用的文献

1
Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors.口服 Xa 抑制剂患者急诊手术中使用的凝血酶原复合物浓缩物。
J Thromb Haemost. 2024 Oct;22(10):2761-2766. doi: 10.1016/j.jtha.2024.07.002. Epub 2024 Jul 11.
2
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.依达赛珠单抗治疗因子 Xa 抑制剂相关急性脑出血。
N Engl J Med. 2024 May 16;390(19):1745-1755. doi: 10.1056/NEJMoa2313040.
3
Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding.
临床指南:严重危及生命出血患者的直接口服抗凝剂逆转。
Eur J Anaesthesiol. 2024 May 1;41(5):327-350. doi: 10.1097/EJA.0000000000001968. Epub 2024 Apr 4.
4
Spontaneous hemothorax caused by rivaroxaban treatment for pulmonary embolism: A case report.利伐沙班治疗肺栓塞导致自发性血胸:一例报告
Clin Case Rep. 2023 Dec 11;11(12):e8333. doi: 10.1002/ccr3.8333. eCollection 2023 Dec.
5
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南:心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
6
Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.使用非维生素 K 拮抗剂口服抗凝剂的房颤患者中 P-糖蛋白和 CYP3A4 相互作用药物对临床结局的影响:一项全国性队列研究。
Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14;9(8):722-730. doi: 10.1093/ehjcvp/pvad070.
7
Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban.基因多态性可能会影响服用阿哌沙班和利伐沙班的患者的出血风险。
Drug Des Devel Ther. 2023 Aug 23;17:2513-2522. doi: 10.2147/DDDT.S417096. eCollection 2023.
8
Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.直接口服抗凝剂治疗的心房颤动患者新型出血风险预测工具 DOAC 评分的制定与验证。
Circulation. 2023 Sep 19;148(12):936-946. doi: 10.1161/CIRCULATIONAHA.123.064556. Epub 2023 Aug 25.
9
Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies.比较在美国接受治疗的老年房颤或急性静脉血栓栓塞症患者中使用利伐沙班与华法林的相关结局:一项观察性研究的系统评价。
Curr Med Res Opin. 2023 Sep;39(9):1183-1194. doi: 10.1080/03007995.2023.2247988. Epub 2023 Aug 24.
10
Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis.利伐沙班治疗期间活化部分凝血活酶时间或凝血酶原时间延长:临床危险因素和结局分析。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231178546. doi: 10.1177/10760296231178546.